Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
RELATED ARTICLES
-
Fresh test for cancer-screening firm Genetron after Nasdaq exit
GTH.US
-
Burning Rock narrows losses with drug research as new driver
BNR.US
- Medical imaging group Rimag sets growth focus with IPO
-
Rebounding Perfect Medical finds beauty safe haven in Hong Kong
1830.HK
-
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
-
New Horizon Health finds formula for profits ahead of schedule
6606.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter